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Cl transportThe aim of the present study is to test the hypothesis that insulin-like-growth factor-1 (IGF-1) plays a role in
the regulation of basolateral Cl channels in the thick ascending limb (TAL). The patch-clamp experiments
demonstrated that application of IGF-I or insulin inhibited the basolateral 10-pS Cl channels. However, the
concentration of insulin required for the inhibition of the Cl channels by 50% (K1/2) was ten times higher
than those of IGF-1. The inhibitory effect of IGF-I on the 10-pS Cl channels was blocked by suppressing pro-
tein tyrosine kinase or by blocking phosphoinositide 3-kinase (PI3K). In contrast, inhibition of phospholipase
C (PLC) failed to abolish the inhibitory effect of IGF-1 on the Cl channels in the TAL. Western blot analysis
demonstrated that IGF-1 signiﬁcantly increased the phosphorylation of phospholipid-dependent kinase
(PDK) at serine residue 241 (Ser241) and AKT at Ser473 in the isolated medullary TAL. Moreover, inhibition
of PI3K with LY294002 abolished the effect of IGF-1 on the phosphorylation of PDK and AKT. The notion
that the effect of IGF-1 on the 10-pS Cl channels was induced by stimulation of PDK–AKT–mTOR pathway
was further suggested by the ﬁnding that rapamycin completely abolished the effect of IGF-1 on the 10-pS
Cl channels in the TAL. We conclude that IGF-1 inhibits the basolateral Cl channels by activating PI3K–
AKT–mTOR pathways. The inhibitory effect of IGF-1 on the Cl channels may play a role in ameliorating the
ischemia-induced renal injury through IGF-1 administration.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
IGF-1, IGF-1 receptor (IGF-1R) and IGF-1 binding proteins are
three important components of IGF-1 system [1,2]. IGF-1 mRNA was
detected in the TAL of Henle's loop in the outer medulla while IGF-
1R mRNA was expressed throughout the kidney including medullary
TAL [3,4]. IGF-1 binding protein mRNA was located in both TAL and
distal convoluted tubule [4]. IGF-1 has been shown to stimulate epi-
thelial Na channels in the collecting duct cells [5]. We have previously
shown that IGF-1 had a biphasic effect on the apical 70 pS K channel
which plays a key role in the apical K recycling in the TAL: IGF-1 at
low concentrations stimulated while at high concentrations inhibited
the apical 70-pS K channels [6]. Since the K recycling is essential for
maintaining the activity of the apical Na/K/Cl cotransporter (NKCC2)
in the TAL [7–9], it is possible that IGF-1-induced inhibition of apicalrmacology, New York Medical
1 914 594 4139; fax: +1 914
ng),
rights reserved.K channels may lead to decreasing NKCC2 activity. It was well docu-
mented that the activity of NKCC2 was also affected by the alteration
in intracellular Cl concentrations [10]. Thus, we speculate that IGF-1
at high concentrations may inhibit not only the apical K channels
but also the basolateral Cl channels in the TAL. This speculation is
also supported by the fact that IGF-1R is highly expressed in the bas-
olateral membrane of renal tubules [11]. Therefore, the aim of the
present study is to explore the role of IGF-1 in regulating the bas-
olateral 10-pS Cl channels which are the main type of Cl channels in
the TAL [12,13].
2. Material and methods
2.1. Preparation of medullary TAL
Sprague–Dawley rats of either sex (70–90 g) were obtained from
the Animal Center of the Second Afﬁliated Hospital of Harbin Medical
University (Harbin, China). The animals were fed with a normal rat
chow. After rats were sacriﬁced with cervical dislocation, both
kidneys were removed immediately and they were cut into several
1-mm thick slices along coronal plane with a razor blade. The kidney
slices were then incubated at 37 °C in a solution containing collagenase
C60 s 1 PA
1 s 1 PA
1. Control
2. IGF-1
IGF-I (200nM)
C
C
0 50 100 150 200 250 300
Ch
a
n
n
e
l a
c
tiv
ity
 (N
P o
)
0.0
0.3
0.6
0.9
1.2
IGF Concentration (nM)
1 2
A
B
*
*
*
*
Fig. 1. (A) A channel recording demonstrating the effect of IGF-1 on the 10-pS Cl chan-
nels in the medullary TAL. The experiments were performed in cell-attached patches
and the holding potential was −60 mV. The arrow indicates the addition of IGF-1.
Two parts of the traces indicated by numbers are extended to show the fast time reso-
lution. The channel closed level is indicated by “C” and a dotted line. (B) A dose–
response curve of IGF-1's effect on the Cl channels in cell-attached patches. Asterisk in-
dicates that the difference is signiﬁcant in comparison to the control value.
1164 L. Wang et al. / Biochimica et Biophysica Acta 1823 (2012) 1163–1169type IA (1 mg/ml) (Sigma, St. Louis, MO) for 45–60 min. After the colla-
genase treatment, the kidney sliceswere rinsed three timeswith a solu-
tion containing (in mM): 140 NaCl, 5 KCl, 1.8 MgCl2, 1.8 CaCl2, and 10
HEPES (pH=7.4) at 4 °C. The tubules were dissected with ﬁne watch-
maker forceps under the dissectionmicroscope. The isolated medullary
TALs were adhered to a cover glass (5×5 mm) coated with Poly-D-
lysine (Sigma, St Louis, MO). The cover glass was transferred into a
chamber (1 ml) mounted on an inverted Nikon microscope and the
TALs were superfused with the HEPES-buffered bath solution con-
taining (in mM) 140 NaCl, 5 KCl, 1.8 CaCl2, 1.8 MgCl2, 5 mM glucose
and 10 HEPES (pH=7.4). The animal protocol was approved by the an-
imal care and use committee of Harbin Medical University.
2.2. Patch-clamp technique
The patch pipettes were pulled with Narishige PP-830 electrode-
puller, polished by WPI MF-83 electrode-polisher, and ﬁlled with
the pipette solution containing (in mM): 140 NaCl, 1.8 MgCl2, and
10 HEPES (pH=7.4). We used an Axon 200B patch-clamp ampliﬁer
to record channel currents which were low-pass ﬁltered at 0.2–
0.5 kHz and digitized by an Axon interface (Digidata 1322). Data
were analyzed using pClamp software system 9.2 (Axon Instruments,
Burlingame, CA). Channel activities were deﬁned as NPo, a product of
channel open probability (Po) and channel number (N). The NPo was
calculated from data samples of 60 s duration in the steady state
using following equation:
NPo ¼ Σ 1 t1 þ 2 t2 þ…itið Þ
in which ti is the fractional open time spent at each of the observed
current levels. We used an all-point histogram to calculate the chan-
nel activity. The slope conductance of the channel was determined
by measurement of the current amplitude at several holding poten-
tials. All experiments were performed in cell-attached patches.
Since the onset time of IGF-1 was typically within 5–6 min, we select-
ed a 60-mins-long recording at the steady state of channel activity at
least 5–6 min after adding IGF-1.
2.3. Western blot
The protein sample (100 μg) obtained from isolated medullary
TAL was separated by electrophoresis using 8% SDS-PAGE and trans-
ferred to nitrocellulose membranes. Membranes were blocked with
5% nonfat dry milk in 0.1% Tween-Tris-buffered saline (TBS-T) and
washed with 0.1% TBS-T. The membranes were incubated overnight
at 4 °C with the corresponding primary antibody. After four time
10-min wash with TBS-T, the membrane was incubated with the sec-
ondary antibody for additional 1 h. ECL plus (Thermo Fisher Scientiﬁc
Inc.) was used to detect the protein bands.
2.4. Chemicals and experimental solution
Antiphospho-Akt-Ser473 and AKT antibodies were obtained from
Cell Signaling Technology (Billerica, MA) while antiphospho-PDK-
Ser241 and PDK antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). IGF-1, insulin and other chemicals were pur-
chased from Sigma (St Louis, MO). IGF-1 and insulin were dissolved
in deionized water containing 0.1% acetic acid and other chemicals
(genestein, herbimycin A, LY294002, wortmannin, U73122, and
rapamycin) were dissolved in DMSO. The ﬁnal concentration of
DMSO in the bath was less than 0.1% and DMSO at 0.1% concentration
did not affect the Cl channel activity. During the experiments we
added genestein, herbimycin A, LY294002, wortmannin, U73122,
and rapamycin to the bath and the tubules were incubated in such
bath solution for at least 5–6 min before applying IGF-1 subsequently.2.5. Statistics
Data are shown as means±SEM. We used paired Student's t-tests
to determine the signiﬁcance of the difference between the control
and experimental periods. Statistical signiﬁcance was taken as
Pb0.05.
3. Results
We conﬁrmed the observations reported by our group and other
investigators that the 10-pS Cl channel was the main type of Cl chan-
nels in the basolateral membrane of the medullary TAL [12,13].
Therefore, the present study is focused on examining the effect of
IGF-1 on the basolateral 10-pS Cl channels. Fig. 1A is a recording
showing Cl channel activity under control conditions and after addi-
tion of IGF-1 (200 nM). The average number of the 10-pS Cl channel
in each patch was two and the mean channel activity (NPo) was
1.03±0.07 (n=10). Application of IGF-1 inhibited the basolateral
10-pS Cl channel in a cell-attached patch within 5–6 min. Fig. 1B is
a dose response curve of IGF-1 effect showing that IGF-1 at concentra-
tions higher than 50 nM signiﬁcantly inhibited the 10-pS Cl channel.
Moreover, application of 300 nM IGF-1 induced a maximal inhibition
of 10-pS Cl channel and decreased channel activity (deﬁned by NPo)
from 1.03±0.07 to 0.05±0.03 (n=10, Pb0.01). We estimated that
the concentration of IGF-1 required for inhibition of Cl channels by
50% (K1/2) was approximately 120 nM. Since IGF-1R could be activat-
ed also by insulin, we examined whether insulin could mimic the ef-
fect of IGF-1 and inhibit Cl channels in the TAL. Fig. 2A is a channel
recording showing the effect of insulin (1 μΜ) on the 10-pS Cl chan-
nels. It is apparent that insulin was able to inhibit the 10-pS Cl chan-
nel within 10 min. However, the inhibitory effect of insulin on the Cl
channels was less potent than that of IGF-1. Fig. 2B is a dose response
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Fig. 2. (A) A channel recording demonstrating the effect of insulin (1 μΜ) on the 10-pS
Cl channels in the medullary TAL. The experiments were performed in cell-attached
patches and the holding potential was−60 mV. The arrow indicates the addition of in-
sulin. Two parts of the traces indicated by numbers are extended to show the fast time
resolution. The channel closed level is indicated by “C” or a dotted line. (B) A dose–
response curve of insulin's effect on the Cl channels in cell-attached patches. Asterisk
indicates that the difference is signiﬁcant in comparison to the control value.
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Fig. 3. A channel recording showing the effect of IGF-1 (200 nM) on the Cl channels in
the presence of herbimycin A (1 μΜ). The top trace shows the time course of the exper-
iments and three parts of the recording indicated by numbers are extended to demon-
strate the fast time course. The channel closed level is indicated by “C” and a dotted
line. The experiments were performed in cell-attached patch and the holding potential
was −60 mV.
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Fig. 4. (A) A channel recording demonstrating the effect of IGF-1 (200 nM) on the Cl chan-
nels in the presence of genistein (10 μΜ). The channel closed level is indicated by a dotted
line and C. The holding potential was −60 mV (hyperpolarization). (B) The bar graph
summarizes the results of experiments in which the effect of IGF-1 on Cl channels was
examined in the absence or in the presence of herbimycin A or genistein (control NPo,
0.98±0.1; IGF-1, 0.24±0.05; genistein, 1.01±0.1; IGF+genistein, 1.03±0.1; her-
bimycin A, 0.97±0.08; IGF+herbimycin A, 0.99±0.1) (n=5–6). “#” indicates a signiﬁ-
cant difference in comparison to the control.
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TAL and the estimated K1/2 value was approximately 1200 nM, a
value ten times higher than that of IGF-1. Thus, the effect of IGF-1
on the Cl channels was speciﬁcally related to IGF-1R. Since 200 nM
IGF-1 caused a sub maximal inhibition of the Cl channels, we used
200 nM IGF-1 throughout the study.
Activation of IGF-1R is expected to stimulate tyrosine kinase activ-
ity through beta-subunit of IGF-1R [14]. Therefore, we examined
whether inhibition of tyrosine kinase activity could abolish the effect
of IGF-1 on the 10-pS Cl channels. Fig. 3 is a channel recording dem-
onstrating the effect of 200 nM IGF-1 on the Cl channels in the TAL
treated with herbimycin A, an inhibitor of protein tyrosine kinase
[15]. Treatment of the TAL with herbimycin A (1 μΜ) did not signiﬁ-
cantly affect the 10-pS Cl channel activity within 10 min (Control
NPo, 0.98±0.1; herbimycin A, 0.97±0.08) (N=6). However, inhibi-
tion of tyrosine kinase abolished the effect of IGF-1 on the Cl channels
(NPo, 0.99±0.1, n=6). In contrast, IGF-1 decreased Cl channel activ-
ity to 0.24±0.05 (n=5) in the absence of herbimycin A (Fig. 4B).
Similar results were observed in the TAL treated with genistein.
Fig. 4A is a channel recording demonstrating that 200 nM IGF-1 failed
to inhibit the 10-pS Cl channels in the presence of genistein (10 μΜ).
Data summarized from 6 experiments were shown in a bar graph
(Fig. 4B) (control NPo, 0.98±0.1; genistein, NPo, 1.01±0.1; genistein+
IGF-1, 1.03±0.1).
After demonstrating the role of tyrosine kinase activity in mediat-
ing the effect of IGF-1 on the basolateral 10-pS Cl channels, we exam-
ined whether PI3K, a downstream signaling molecule of IGF-1
pathway, was involved in modulating the effect of IGF-1 on the
10-pS Cl channels. Fig. 5A is a representative channel recording in a
cell-attached patch demonstrating that treatment of the mTAL with
LY294002 (10 μΜ), a speciﬁc inhibitor of PI3K [16], abolished the
effect of 200 nM IGF-1 on 10-pS Cl channels. Results summarized in
Fig. 5B show that 200 nM IGF-1 failed to inhibit the 10-pS Cl channel(control NPo, 1.02±0.1; LY294002, 1.08±0.1; LY294002+IGF-1,
1.06±0.1) (N=7). The same results were observed with wortmannin,
another speciﬁc inhibitor of PI3K [17]. Fig. 5C is a channel recording
showing that the effect of IGF-1 on the Cl channels was absent in the
mTAL treated with 100 nM wortmannin. Data summarized in Fig. 5B
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Fig. 5. (A) A channel recording demonstrating the effect of IGF-1 (200 nM) on the Cl channels in the presence of LY294002 (10 μΜ). (B) The bar graph summarizes the results of
experiments in which the effect of IGF-1 on Cl channels was examined in the absence or in the presence of LY294002 or wortmannin (control NPo, 1.02±0.1; IGF-1, 0.23±0.05,
LY294002 (LY), 1.08±0.1; IGF+LY, 1.06±0.1; wortmannin, 1.15±0.08; IGF+wortmannin, 1.08±0.1) (n=5–7). “#” indicates a signiﬁcant difference in comparison to the con-
trol. (C) A channel recording demonstrating the effect of IGF-1 (200 nM) on the Cl channels in the presence of wortmannin (100 nM). The experiments were performed in cell-
attached patch and the holding potential was −60 mV.
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Fig. 6. (A) A channel recording demonstrating the effect of IGF-1 (200 nM) on the Cl
channels in the presence of U73122 (5 μΜ). (B) A bar graph summarizing experiments
in which the effect of IGF-1 on the Cl channels was examined in the presence of U73122
(control NPo, 1.19±0.1; IGF-1, 0.23±0.07; U73122, 1.3±0.13; IGF+U73122, 0.27±0.1)
(n=4–5) The experiments were performed in cell-attached patch and the holding poten-
tial was−60 mV.
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effect on the Cl channel activity in the TAL treated with wortmannin
(wortmannin NPo, 1.15±0.08; wortmannin+IGF-1, 1.08±0.08)
(n=6). The results suggest that PI3K is involved inmediating the effect
of IGF-1 on the Cl channels in the TAL.
Activation of PI3K has been shown to stimulate phospholipase C
(PLC) or AKT [18,19]. Therefore, we ﬁrst examined the role of PLC in
mediating the effect of IGF-1 on the 10-pS Cl channels in the TAL.
Fig. 6A is a channel recording demonstrating the effect of 200 nM
IGF-1 on the 10-pS Cl channel in the presence of U73122 (5 μM). In-
hibition of PLC did not signiﬁcantly affect the basal activity of the
10-pS Cl channels (NPo, 1.31±0.13), a value not signiﬁcantly differ-
ent from the control (NPo=1.19±0.12) (Fig. 6B). However, addition
of 200 nM IGF-1 decreased NPo to 0.27±0.1 in the presence of
U73122, suggesting that the effect of IGF-1 was not mediated by
PLC dependent pathway.
Stimulation of PI3K has been demonstrated to activate AKT either
by PDK or by phosphatidylinositol (3,4,5)-triphosphate (PIP3) [19].
To test whether IGF-1 activates PDK in the TAL, we examined the ef-
fect of IGF-1 on PDK phosphorylation using antibody reacting to
phosphorylated PDK at serine residue 241 (P-PDKS241), an indication
of PDK activation [20], in the isolated medullary TAL treated with
200 nM IGF-1 for 5, 15, 30 min, respectively. Fig. 7A is a Western
blot demonstrating the time course of IGF-1 on PDK phosphorylation.
It is apparent that incubation of the medullary TAL with 200 nM IGF-1
for 5 min increased P-PDKS241 by 190±20% (N=3 rats). Results were
also consistent with the patch-clamp experiments in which IGF-1
inhibited 10-pS Cl channels within 5–6 min (Fig. 1). We next exam-
ined the dose response curve of the effect of IGF-1 on PDK phosphor-
ylation by treating the medullary TAL with 100, 200 and 300 nM
IGF-1 for 5 min. As shown in Fig. 7B, 200 nM IGF-1 caused a sub-
maximal stimulation of P-PDKS241 by 195±20%. To determinewhetherIGF-1-induced stimulation of P-PDKS241 was PI3K-dependent, we ex-
amined the effect of IGF-1 on the phosphorylated PDK in the presence
of LY294002. From inspection of Fig. 7C, it is apparent that inhibition
P-PDKS241
PDK
β-actin 
0 5 15 30 min 0       100    200     300 nM LY    LY+IGF  IGF   Control
IGF-I (200nM)
PDK
β-actin 
PDK
β-actin 
0
50
100
150
200
LY  LY+IGF IGF Control
*
A CB
P-PDKS241 P-PDK
S241
0
50
100
150
200
250
300 nM IGF  200100   0
*
*
*
0
50
100
150
200
N
or
m
al
iz
ed
 in
te
ns
ity
 
(%
 
)
(P
-P
DK
S2
41
 
)
N
or
m
al
iz
ed
 in
te
ns
ity
 
(%
 
)
(P
-P
DK
S2
41
 
)
N
or
m
al
iz
ed
 in
te
ns
ity
 
(%
 
)
(P
-P
DK
S2
41
 
)
0 min  5 min 15 min 30 min IGF-1
*
*
*
IGF-I 
Fig. 7. (A) AWestern blot showing the effect of IGF-1 (200 nM) on PDK phosphorylation with P-PDKS241 at 5, 15 and 30 min, respectively. Results were summarized in the bottom of
the ﬁgure. (B) A Western blot showing the effect of IGF-1 treatment (5 min) on PDK phosphorylation with P-PDKS241 at 100, 200 and 300 nM, respectively. Results were summa-
rized in the bottom of the ﬁgure. (C) A Western blot showing the effect of IGF-1 treatment (200 nM for 5 min) on the PDK phosphorylation in the medullary TAL treated with or
without LY294002. Results were summarized in the bottom of the ﬁgure. Asterisk indicates a signiﬁcant difference in comparison to the control.
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(90±10% of the control value) (N=3 rats).
Not only stimulating PDK phosphorylation, IGF-1 (200 nM) also
increased phosphorylation of AKT at Ser473 (P-AKTS473), an indication
of AKT activation [20]. Fig. 8A is a Western blot from 3 similar exper-
iments (3 rats) in which the effect of 200 nM IGF-1 on P-AKTS473 was
examined with speciﬁc antibody reacting with Ser473 of AKT in the
isolated medullary TAL treated with or without 10 μΜ LY294002.
IGF-1 increased the AKT phosphorylation by 180±20%, an effect
that was absent in the medullary TAL treated with LY294002
(Fig. 8B). Therefore, the results strongly suggest that IGF-1-induced
inhibition of the basolateral 10-pS Cl channel is mediated by PDK–
AKT pathways.
AKThas been shown to activatemTORdirectly through the phosphor-
ylation or indirectly through tuberous-sclerosis-complex-dependent
mechanism [19]. To examine the role of mTOR, we used rapamycin,P-AKT S473
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Fig. 8. (A) AWestern blot showing the effect of IGF-1 treatment (200 nM for 5 min) on
the AKT phosphorylation in the medullary TAL treated with or without LY294002
(10 μΜ). (B) Results were summarized in the bottom of the ﬁgure. Asterisk indicates
a signiﬁcant difference in comparison to the control.which speciﬁcally binds to and inhibits the mTOR [21,22]. Rapamycin
has been widely used as a tool for exploring the role of mTOR in mediat-
ing the function of IGF-1 in a variety of tissue [23–25].We testedwhether
inhibition of mTOR was able to block the effect of IGF-1 on the 10-pS Cl
channels. Fig. 9A is a representative channel recording showing that
IGF-1 did not inhibit the 10-pS Cl channel in the presence of rapamycin
(100 nM). Fig. 9B summarizes the results from six experiments showing1 s
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Fig. 9. (A) A channel recording demonstrates the effect of 200 nM IGF-1 on the 10-pS Cl
channels in the presence of rapamycin (100 nM). The experiments were performed in
cell-attached patches and the holding potential was−60 mV. (B) A bar graph summa-
rizing experiments in which the effect of IGF-1 on the Cl channels was examined in the
presence of rapamycin (control NPo, 1.01±0.1; IGF-1, 0.24±0.06; rapamycin, 1.14±0.1;
IGF+rapamycin, 1.1±0.1) (n=4–6). “#” indicates a signiﬁcant difference in comparison
to the control.
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1168 L. Wang et al. / Biochimica et Biophysica Acta 1823 (2012) 1163–1169that rapamycin abolished the inhibition of the Cl channels by IGF-1 (1.1±
0.1) while it had no signiﬁcant effect on the channel activity (NPo,
1.14±0.1) (N=6). Therefore, the results suggest the role of mTOR in
mediating the inhibitory effect of IGF-I on the 10-pS Cl channel in the TAL.
4. Discussion
The main ﬁnding of the present study is that IGF-1 inhibits the
basolateral 10-pS Cl channels by PI3K-dependent pathway. Although
insulin could also inhibit the 10-pS Cl channel, the K1/2 value was one
order of magnitude higher than those of IGF-1, suggesting that the
effect of insulin may be mediated by stimulating IGF-1R. Thus, IGF-
1R may play a role in regulating basolateral Cl conductance. The Cl
channel plays an important role in maintaining NaCl transport in
the TAL [26]. The transepithelial Cl transport in the TAL is achieved
by a two-step process: Cl enters the cell through the apical NKCC2
and leaves the cells through the basolateral Cl channels or KCl
cotransporter [27]. Molecular cloning has identiﬁed two types of Cl
channels, ClC-K1 and ClC-K2 in the Henle's loop [28,29]. Moreover,
immunostaining demonstrates that ClC-K1 is mainly expressed in
the thin ascending limb of Henle's loop [30] while ClC-K2 is predom-
inantly expressed in the basolateral membrane of the TAL in the rat
kidney [31], suggesting that ClC-K2 is responsible for the basolateral
Cl conductance. This view is strongly indicated by the ﬁnding that de-
fective gene product encoding either ClC-K2 or barttin caused type IV
Bartter's syndrome [32]. Patch-clamp studies have demonstrated that
two types of Cl channels, an 8–9 pS and a 20–40 pS, are expressed in
the basolateral membrane of the TAL and that the 8–9 pS Cl channel is
a main type of Cl channels expressed in the basolateral membrane
[13]. Thus, it is most likely that 10-pS Cl channel is the gene product
of ClC-K2. Therefore, inhibition of the basolateral Cl channels by
IGF-1 is expected to increase the intracellular Cl concentration there-
by decreasing the activity of NKCC2 in the TAL by inhibition of Ste20-
related proline/alanine-rich kinase [10].
It is well documented that activation of IGF-1R stimulates the ty-
rosine phosphorylation of IGF-1R's β-subunit thereby initiating IGF-
mediated signaling pathway [14]. The observation that inhibition of
tyrosine kinase activity abolished the inhibitory effect of IGF-1 on
the basolateral 10-pS Cl channels strongly suggests the role of tyro-
sine kinase in mediating the effect of IGF-1 on the Cl channels. We
proposed that the effect of IGF-1 on the basolateral 10-pS Cl channels
is mediated by PI3K–AKT–mTOR pathways. First, suppressing PI3K or
mTOR completely abolished the inhibition of the Cl channels by IGF-1.
Second, application of IGF-1 increased PDK phosphorylation at Ser241
and AKT at Ser473. Third, inhibition of PI3K abolished the effect of
IGF-1 on PDK and AKT phosphorylations in the TAL.
IGF-1 has been shown to increase renal blood ﬂow and glomerular
ﬁltration rate in the kidney [33,34] and to facilitate the tubular re-
modeling and repair after ischemic insult [35]. We have previously
demonstrated that IGF-1 regulates the apical 70-pS K channels in
the TAL by a biphasic manner: IGF-1 at low concentrations stimulates
while at high concentrations inhibits the 70-pS K channels [6]. In the
present study, IGF-1 at physiologically relevant concentrations (less
than 50 nM) had no effect on the Cl channels while at high concentra-
tions IGF-1 inhibited the Cl channels in the TAL. Insulin and IGF-1
have been shown to increase transepithelial Na transport in the
aldosterone-sensitive distal nephron by stimulation of amiloride-
sensitive ENaC [5,36,37]. Moreover, acute IGF-1 infusion at 50 nM
has been shown to induce antidiuretic and antinatriuretic effects by
increasing phosphorylation of NKCC2 [38]. In contrast, the present
study demonstrated that IGF-1 at concentrations larger than 50 nM
inhibited the basolateral Cl channels. The discrepancy may be
induced not only by different nephron segments (collecting duct vs
TAL) but also different concentrations of insulin or IGF-1 used in
experiments. It is possible that IGF-1/insulin at physiological concen-
trations may stimulate renal Na absorption but it has no effect on thebasolateral Cl channels. However, IGF-1 at high concentrations might
decrease Na absorption through inhibition of Cl transport in the TAL.
Relevant to our hypothesis is the report that natriuretic response
induced by loop diuretics was lower in rats with high basal level of
IGF-1 and other growth hormones (GC rats) than those of the control
rats [36]. IGF-1-induced increase in ENaC activity in the aldosterone-
sensitive distal nephron may be partially responsible for the dimin-
ished effect of furosemide on renal Na excretion [36]. However, it is
also possible that IGF-1 may decrease Na transport in the mTAL by
directly inhibiting NKCC2 or through inhibiting basolateral Cl chan-
nels thereby indirectly decreasing NKCC2 activity in the TAL. Thus,
furosemide-induced natriuretic effect in the TAL is attenuated in
rats with high IGF-1 level. The notion that IGF-1 may differently reg-
ulate ENaC in the collecting duct and basolateral Cl channels in the
TAL is also suggested by the report that renal Na excretion in GC
rats was not signiﬁcantly different from those of the control rats
with a normal basal level of IGF-1 [36].
It has been shown that normal plasma concentrations of IGF-1 in
rats or mice are between 340 and 400 ng/ml or 45 and 50 nM under
physiological conditions [39,40] and the serum levels of IGF-1 in
human is between 25 and 40 nM. [41]. Thus, the concentrations of
IGF-1 used in the present study were not in the physiological relevant
ranges. However, it has been shown that the bioavailability of IGF-1
might increase signiﬁcantly by lowering IGF-1 binding protein after
acute renal failure [42]. Moreover, infusion of IGF-1 has been shown
to ameliorate transient ischemia-induced acute renal failure in rats
[43] and to facilitate the renal recovery after ischemia-induced
acute renal failure [44]. IGF-1 has been used in the clinical practice
to treat acute or chronic renal failure [45]. Fig. 10 is a cell scheme
illustrating a possible mechanism by which IGF-1 inhibits the bas-
olateral 10-pS Cl channels in the medullary TAL. Since the 10-pS Cl
channel is the main type of the Cl channels in the basolateral mem-
brane of the TAL, inhibition of the basolateral Cl channels by IGF-1
is expected to diminish the transepithelial Cl absorption thereby de-
creasing oxygen consumption in the medullary TAL. Thus, IGF-1-
induced inhibition of the basolateral Cl channels could be a possible
factor which protects the TAL after ischemia. We conclude that
IGF-1 inhibits the basolateral 10-pS Cl channels in the TAL by PI3K–
AKT–mTOR pathways. The signiﬁcance of the present ﬁnding may
illustrate a new mechanism by which IGF-1 protects kidney from
1169L. Wang et al. / Biochimica et Biophysica Acta 1823 (2012) 1163–1169ischemia-induced injury through suppressing transepithelial Cl trans-
port in the medullary TAL.
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